A post-authorization study to assess the safety and efficacy of Fanhdi (Double-inactivated human anti-hemophilic factor) in subjects with Von Willebrand disease (PostAuthorization Study with Fanhdi in VWD patient)

First published 02/11/2018

Last updated 22/02/2024

EU PAS number:

EUPAS25809

Study

Finalised

Documents

Study protocol

Initial protocol

IG1403 Protocol V3.0 2018.05.18

English (872.73 KB - PDF)View document

Updated protocol

Protocolo v 4.0 (2021_01_20)_redacted

First published: 22/02/2024

English (7.88 MB - PDF)View document

Study results

2-synopsis_redacted

English (1.2 MB - PDF)View document

Study report

Other information

Secondary tabs